(S1 (S (S (NP (NP (DT An) (NN antibody)) (VP (VBN directed) (PP (IN against) (NP (NN PDGF) (NN receptor) (NN beta))))) (VP (VBZ enhances) (NP (NP (DT the) (NN antitumor)) (CC and) (NP (NP (DT the) (JJ anti-angiogenic) (NNS activities)) (PP (IN of) (NP (DT an) (JJ anti-VEGF) (NN receptor) (CD 2) (NN antibody))))))) (. .)))
(S1 (S (S (NP (NP (NP (JJ Platelet-derived) (NN growth) (NN factor)) (PRN (-LRB- -LRB-) (NP (NN PDGF)) (-RRB- -RRB-))) (CC and) (NP (NP (PRP$ its) (NNS receptors)) (PRN (-LRB- -LRB-) (NP (NN PDGFR)) (-RRB- -RRB-)))) (VP (VBP play) (NP (JJ important) (NNS roles)) (PP (IN in) (NP (NN tumorigenesis))) (PP (IN through) (S (VP (VP (VBG stimulating) (NP (NN tumor) (NN growth))) (CC and) (VP (VBG promoting) (NP (NN angiogenesis)) (PP (IN via) (S (VP (VBG enhancing) (NP (NP (NN pericyte) (NN recruitment)) (CC and) (NP (NN vessel) (NN maturation)))))))))))) (. .)))
(S1 (S (S (ADVP (RB Here)) (NP (PRP we)) (VP (VBD produced) (NP (NP (NP (DT a) (VBG neutralizing) (NN antibody)) (, ,) (NP (NN 1B3)) (, ,)) (VP (VBN directed) (PP (IN against) (NP (NN mouse) (NN PDGFRbeta))))))) (. .)))
(S1 (S (S (NP (NN 1B3)) (VP (VP (VBZ binds) (PP (TO to) (NP (NN PDGFRbeta))) (PP (IN with) (NP (NP (JJ high) (NN affinity)) (PRN (-LRB- -LRB-) (NP (NN 9x10-LRB--11-RRB-M)) (-RRB- -RRB-))))) (CC and) (VP (VBZ blocks) (NP (NN PDGF-BB)) (PP (IN from) (S (VP (VBG binding) (PP (TO to) (NP (DT the) (NN receptor))) (PP (IN with) (NP (NP (DT an) (NN IC-LRB-50-RRB-)) (PP (IN of) (NP (QP (RB approximately) (CD 1.2)) (NN nM))))))))))) (. .)))
(S1 (S (S (NP (DT The) (NN antibody)) (ADVP (RB also)) (VP (VBZ blocks) (NP (NP (JJ ligand-stimulated) (NN activation)) (PP (IN of) (NP (NP (NN PDGFRbeta)) (CC and) (NP (NP (JJ downstream) (VBG signaling) (NNS molecules)) (, ,) (PP (VBG including) (NP (NP (NN Akt)) (CC and) (NP (NN MAPK) (CD p42/44)))) (, ,)))) (PP (IN in) (NP (NN tumor) (NNS cells)))))) (. .)))
(S1 (S (PP (IN In) (NP (NN animal) (NNS studies))) (, ,) (NP (NN 1B3)) (ADVP (RB significantly)) (VP (VBD enhanced) (NP (NP (DT the) (NN antitumor)) (CC and) (NP (NP (DT the) (JJ anti-angiogenic) (NNS activities)) (PP (IN of) (NP (NP (NN DC101)) (, ,) (NP (NP (DT an) (NN antibody)) (VP (VBN directed) (PP (IN against) (NP (NN mouse) (JJ vascular) (JJ endothelial) (NN growth) (NN factor) (NN receptor) (CD 2))))) (, ,))))) (PP (IN in) (NP (NP (NP (DT a) (JJ pancreatic)) (PRN (-LRB- -LRB-) (NP (NN BxPC-3)) (-RRB- -RRB-))) (CC and) (NP (NP (DT a) (JJ non-small) (NN cell) (NN lung)) (PRN (-LRB- -LRB-) (NP (NN NCI-H460)) (-RRB- -RRB-))) (NP (NN tumor) (NN xenograft) (NNS models))))) (. .)))
(S1 (S (S (NP (NP (NN Treatment)) (PP (IN with) (NP (NP (DT the) (NN combination)) (PP (IN of) (NP (NP (NN 1B3)) (CC and) (NP (NN DC101)))))) (PP (IN in) (NP (NN BxPC-3) (JJ xenograft-bearing) (NNS mice)))) (VP (VBD resulted) (PP (IN in) (NP (NP (NN tumor) (NN regression)) (PP (IN in) (NP (NP (CD 58) (NN %)) (PP (IN of) (NP (NNS mice))))))) (S (VP (VBN compared) (PP (TO to) (NP (NP (DT that)) (PP (IN in) (NP (NP (CD 18) (NN %)) (PP (IN of) (NP (NP (NNS mice)) (VP (VBN treated) (PP (IN with) (NP (NN DC101))) (ADVP (RB alone))))))))))))) (. .)))
(S1 (S (S (S (VP (VBN Taken) (ADVP (RB together)))) (, ,) (NP (DT these) (NNS results)) (VP (VBP lend) (NP (JJ great) (NN support)) (S (VP (TO to) (VP (VB use) (NP (NP (NN PDGFRbeta) (NNS antagonists)) (PP (IN in) (NP (NP (NNS combinations)) (PP (IN with) (NP (JJ other) (ADJP (ADJP (JJ antitumor)) (CC and/or) (ADJP (JJ anti-angiogenic))) (NNS agents)))))) (PP (IN in) (NP (NP (DT the) (NN treatment)) (PP (IN of) (NP (NP (DT a) (NN variety)) (PP (IN of) (NP (NNS cancers)))))))))))) (. .)))
